Forstpointner R et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003–4008
Treatment with a combination of rituximab and chemotherapy (R-chemotherapy) improves the prognosis of patients with follicular lymphomas (FLs) or mantle-cell lymphomas (MCLs). Forstpointner et al. have now demonstrated that maintenance therapy with rituximab (R-maintenance) after R-chemotherapy results in an improved response in lymphoma patients who are responsive to initial R-chemotherapy.
The study included patients with refractory or recurring FL or MCL who were randomized to receive fludarabine, cyclophosphamide and mitoxantrone (FCM) alone or together with rituximab (R-FCM). High response rates were observed in the R-FCM arm and 176 of these responsive patients were subsequently randomized to receive R-maintenance or no further treatment. All patients in the R-maintenance arm had a prolonged response duration compared with patients who received no maintenance (P = 0.001), and this benefit of R-maintenance remained when the analysis was restricted to patients who had received initial R-FCM therapy (P = 0.035 for those with FL and P = 0.049 for those with MCL). The estimated percentages of patients alive at 3 years were 77% after R-maintenance therapy and 57% after no maintenance (P = 0.100).
These results demonstrate that the antilymphoma activity of rituximab is maintained through all phases of treatment, and indicate that R-maintenance is a promising therapy for patients with FLs and those with MCLs, producing no significant side effects.
Rights and permissions
About this article
Cite this article
Prolonged response duration in lymphoma after rituximab maintenance therapy. Nat Rev Clin Oncol 4, 140 (2007). https://doi.org/10.1038/ncponc0720
Issue Date:
DOI: https://doi.org/10.1038/ncponc0720